94results about How to "Good tumor targeting" patented technology

The invention relates to a chimeric antigen receptor (CAR) and application thereof. The CAR comprises BCMA (B-cell maturation antigen) binding structural domains, transmembrane structural domains, oneor a plurality of co-simulation structural domains and intracellular signal transduction structural domains. The BCMA binding structural domains comprise heavy chain complementary determining regionsHCDR 1-3, and amino acid sequences of the HCDR 1-3 are sequentially shown as SEQ ID NO:1-3.

The invention provides a nanofiber membrane and a preparation method and application thereof. The nanofiber membrane is formed by fibers of a core-shell structure and is characterized in that the core is formed by mixed fibers mixed by polylactic acid-hydroxyacetic acid and polycaprolactone, the shell is formed by fibers formed by gelatin crosslinking with genipin, and the core is loaded with chemical therapy medicine. The nanofiber membrane prepared by the coaxial electrospinning technology has an in-situ anti-cancer function and is implantable, good in biocompatibility, free of cytotoxicity to normal cells and good in curative effect on tumor. The preparation method is simple, mild in condition, low in cost and easy to popularize and apply.

The invention relates to a tumor-targeted sound and light power medicine-carrying nanometer nano-micelle, and a preparation method and a purpose thereof. The medicine-carrying nanometer nano-micelle is structurally characterized in that porphyrins compounds and anthracyclines chemotherapeutic medicine form a nanometer composition through a pi-pi conjugation effect; and amphiphilic block copolymers with PEO (polyoxyethylene) or PEG (polyethylene glycol) hydrophilic segments cover nanometer compounds through the hydrophobic effect to form a hydrophilic case. The medicine-carrying nanometer nano-micelle is in a regular spherical form, and has the advantages of uniform distribution, stable property and high medicine carrying capacity; the medicine can be conveyed to the tumor focus in the targeted way and can be effectively enriched in the tumor tissue; under the ultrasound (illumination) condition, the treatment effect of the anthracyclines chemotherapeutic medicine on the tumor can be obviously enhanced; and the tumor drug resistance can be effectively reversed. Wide clinic application prospects can be realized in an aspect of combined tumor treatment by a sound (light) power therapy method and chemotherapy.

The invention relates to a fusion protein of an IFN and an anti-PD-L1 antibody, a pharmaceutical composition containing the fusion protein and a kit as well as an application of the fusion protein intumor treatment. The fusion protein can be targeted to PD-L1 and IFN receptors at the same time. An IFN signal in a tumor microenvironment is activated by inducing more powerful T cell activation to enhance PD-1/PD-L1 treatment on tumors; meanwhile, the anti-PD-L1 antibody can be used for specifically transferring immunoregulation molecules to tumor tissues. The fusion protein acts to generate multiple feedforward responses, so that the targeting effect is increased and the toxicity is reduced, and response to IFN treatment is enhanced, so that the anti-tumor effect is maximized.

The invention discloses BrBP1 polypeptide in specific binding with breast cancer brain metastases cells, and further relates to a preparation method of the polypeptide. The method includes: by utilization of phage display technology, carrying out a plurality of rounds of whole-cell depletion screening, and screening out phage clones bound with a breast cancer brain metastases cell line; randomly picking out a plurality of the phage clones, and selecting strongly positive phage clones with a cell enzyme-linked immuno sorbent assay (ELISA) method; and after increasing the strongly positive phage clones, carrying out sequencing, and synthesizing the tested BrBP1 polypeptide in a manual mode. The polypeptide can be applied to preparation of medicine used for curing breast cancer brain metastases and kits used for early-stage diagnosis of the breast cancer brain metastases. The polypeptide can be synthesized with a manual method, is small in molecular weight, high in activity, strong in penetrating power, high in affinity and specificity and low in toxicity, has good tumor-targeting performance inside and outside a body, can also be internalized to enter cells, and is suitable for being used as vectors for targeted therapy.

The invention relates to a polypeptide capable of specific tumor-binding. The amino acid sequence of the polypeptide is shown as SEQ ID No.1. According to the invention, phages specifically binding with lung cancer are obtained by means of a phage display in vivo screening method to determine sequence in order to synthesize the specific binding polypeptide. The polypeptide can achieve excellent in vitro binding with a plurality of tumor cells subsequent to the conjunction with poly(amidoamine) dendrimer nano material. As verified by in vitro experiments, the target polypeptide has a very hightumor targeting effect and can be widely used as a targeting agent in diagnostic imaging and targeted treatment of tumors.

The invention belongs to the field of medical technology and relates to an integrin targeting drug loaded albumin nanoparticle formulation and its preparation method. According to the invention, a gemcitabine-carried albumin nanoparticle target administration system is prepared by gemcitabine raw medicine, bovine serum albumin BSA, a RGD polypeptide, injection water, a dehydrating agent, a cross-linking agent and sodium hydroxide. The drug-loaded albumin nanoparticles have good dispersibility with a distribution range of particle size being 94-166nm, average particle size being 130nm, Zeta potential being -30.77mV, an encapsulation efficiency being 92.16%, a drug loading capacity being 12.8%, 30min burst release rate being 53.25+/-2.23% and 8 hours in vitro cumulative release rate reaching 90%. It is verified through experiments that the targeted nanoparticles provided by the invention can significantly increase the drug accumulation in the target sites, have good slow release and tumor targeting effects, can improve therapeutic effects and relieve toxic and side effects of chemotherapeutic drugs and enhance the tolerance of patients to treatment.

The invention relates to preparation of glutamic acid-polyethylene glycol monostearate and application of the amphipathic target material modified nano-particles in disease target transfer. According to the amphipathic target material, glutamic acid is used as a target head, polyethylene glycol is used for improving the flexibility of the target head, and hydrophobic monostearate is used as an anchoring position with polyglycolic-polylactic acid copolymer. The target material modified nano-particles can be used as a target transfer tool of multiple anti-tumor drugs, and interacts with high-expression big neutral amino acid transporter 1 on a tumor cell membrane by the surface modified glutamic acid, so that the cell uptake and anti-tumor activity of the nano-particles can be effectively improved. The nano-particles have good stability, excellent target performance, can be used in intravenous injection, and have a relatively large market application prospect.

The invention discloses a targeted polypeptide for vitro and vivo early diagnosis or treatment of lung cancer, belonging to the medicine technical field. The polypeptide is dodecapeptide. The invention also discloses the application of the targeted polypeptide. The targeted polypeptide is applied to a carrier of the targeted therapy of the lung cancer or the preparation of anti-cancer drugs, or used as the medicine of early period and the middle period diagnosis of the lung cancer. The polypeptide provided by the invention is small micro molecule antibody and has smaller antibody molecular weight and strong penetrating power, is easy to reach tumor tissues and can be more sensitive to diagnose the tumor apart from having the advantages of the traditional antibody medicine, thus being in favor of the early diagnosis of the tumor. The polypeptide has good targeted function of the tumor, is suitable for the targeted treatment or the carrier of the targeted treatment and has wide application prospect.

The invention discloses a lovastatin silicon plastid of a targeted breast cancer stem cell and a preparation method thereof.The lovastatin silicon plastid is prepared from, by weight, lovastatin 2%-30%, organic-inorganic compound lipid 20%-70%, phosphatidyl ethanolamine-polyethylene glycol 2000 1%-20% and distearoyl phosphatidylcholine 10%-60%.The lovastatin silicon plastid overcomes the shortcoming that the bioavailability of lovastatin drugs in the prior art is low.

The invention provides new application of artemisinin and a derivative thereof, namely that the artemisinin or the derivative thereof is directly used as a sensitizer for thermodynamic therapy, and isused for thermodynamic therapy of tumors; or a liposome nano-composite prepared from the artemisinin and the derivative thereof and indocyanine green is used as a sensitizer for the thermodynamic therapy, and is used for thermodynamic therapy and/or photothermal therapy of the tumors. when being used for thermodynamic therapy of the tumors, the artemisinin or the derivative thereof and the liposome nano-composite not only show excellent tumor targeting performance, but also have extremely high synergistic photothermal therapy and thermodynamic therapy anti-tumor activity, and have remarkableadvantages as an anti-cancer drug.

The invention belongs to the field of pharmaceutical preparations, and relates to a deoxypodophyllotoxin medicine-containing pharmaceutical composition and a preparation method and a preparation thereof. The deoxypodophyllotoxin medicine-containing pharmaceutical composition comprises a deoxypodophyllotoxin medicine and hyaluronic acid-5 beta cholanic acid, and the hyaluronic acid-5 beta cholanic acid coats the deoxypodophyllotoxin medicine in micellar form. The invention also discloses the preparation method and application of the pharmaceutical composition. The deoxypodophyllotoxin medicine-containing pharmaceutical composition has excellent tumor targeting property and good safety, reduces the toxic and side effects, improves the curative effect, can be used for intravenous injection, and has good application prospect in tumor target drug application system research and tumor treatment.

The invention belongs to the technical field of biological medicines, and discloses a betulinic acid derivative, a preparation method and application thereof. The preparation method comprises the following steps: preparing biotin esterification coupled oligomerization ethylene glycol carboxylic acid or biotin amide coupled oligomerization ethylene glycol carboxylic acid; dissolving betulinic acidin a solvent, and carrying out a stirring reaction at 0 DEG C for 1-6 hours under the action of a dehydrating agent and a catalyst; adding biotin or the biotin esterification coupled oligomerization ethylene glycol carboxylic acid or biotin amide coupled oligomerization ethylene glycol carboxylic acid according to a betulinic acid molar ratio of 1:1-3, heating to room temperature from an ice bath,and stirring in a dark place overnight; and concentrating the filtrate, re-crystallizing with ice diethyl ether or isopropanol, carrying out chromatography or preparative liquid phase purification, and freeze-drying to obtain the betulinic acid derivative. The betulinic acid derivative, the pharmaceutically acceptable salt and the isotope marker thereof can be applied to preparation of anti-cancer drugs and drugs for treating obesity or non-alcoholic fatty liver disease.

The invention discloses a preparation method of copper porphyrin-folate liposome nanoparticles and application thereof as a sound-sensitive agent. The preparation method comprises the following steps:dissolving copper porphyrin with methanol, dissolving lecithin and folate liposome in chloroform, mixing the two solutions, preparing a lipid film by a rotary evaporation method, and carrying out ultrasonic hydration with ultrapure water to synthesize the copper porphyrin-folate liposome nanoparticles. The nanoparticles have excellent targeting property in tumor cells with high expression of folate receptors, and are beneficial to enrichment at tumor sites so as to improve the anti-tumor effect; and under ultrasonic excitation, the copper porphyrin absorbs sound energy to generate transitionand converts surrounding oxygen into singlet oxygen to kill tumor cells. The invention provides the sound-sensitive agent capable of generating singlet oxygen through ultrasonic excitation to kill thetumor cells, and the folate targeted liposome is used as a carrier to carry the sound-sensitive agent, so that the water solubility and the targeting property are improved, and the sonodynamic therapy (SDT) effect is further improved.

The invention discloses a magnetic targeting cell membrane modified ligand, a drug-loading material, a preparation method of the magnetic targeting cell membrane modified ligand and the drug-loading material and an application of the drug-loading material. The structural general formula of the magnetic targeting cell membrane modified ligand is shown as I series or II series in the formula (1). The magnetic targeting cell membrane drug-loading material is obtained by performing chemical covalent bond modification on a cell membrane to modify the magnetic targeting cell membrane modified ligand, an in-vitro test shows that the material is good in stability, can be effectively taken in by tumor cells, and has relatively high selectivity on the tumor cells, and besides, the material has remarkable paramagnetism. Under the condition of an external magnetic field, a magnetic targeting effect can be achieved. In an in-vitro anti-tumor test, the drug-loading material is remarkable in anti-tumor activity and hardly has toxicity to normal cells, so that the drug-loading material has a potential application of targeted therapy of malignant tumors.

The invention relates to a high-penetrability tumor target lipid insert and a preparation method thereof. The insert is prepared from a high-penetrability peptide iRGD containing ingredient and DSPE-PEG-MAL, and can be inserted onto a plurality of drug-loaded systems and cells to realize active tumor target. According to the preparation method, the substance of the high-penetrability peptide iRGD containing ingredient serving as a molecule for realizing tumor active target and high penetrability is used for modifying a segment of lipid molecules to form a multi-functional tumor target insert capable of definitely reinforcing tumor target. Repeated experiments after successful construction verify that the tumor target lipid insert has definite tumor targeting and can be used for actually reinforcing tumor local aggregation of cell and cell membrane preparations and improving the anti-tumor treatment effect.

The invention provides a near-infrared quantum dot probe for the brain glioma tracing. The probe uses a carboxylated poloxamer, and a cyclic glycyl-arginyl-glycyl-aspartyl-asparaginyl-proline short peptide grafted poloxamer as materials, near-infrared quantum dots and a cysteine-alanine-glutamine-lysine tetrapeptide are encapsulated, nanomicelles are formed by the self-assembly in an aqueous solution, and a solution of the near-infrared quantum dot probe that specifically binds to integrin alpha v beta 3 overexpressed by glioma cells is formed. The near-infrared quantum dot probe has the characteristics of uniform particle size, high stability, good tumor targeting, and strong tissue penetration. The brain glioma tracing with high efficiency, targeting and specificity can be realized by combining the ultrasound-targeted micro-bubble blasting technology to reversibly open the blood-brain barrier.

The invention provides a fusion vesicle derived from bacteria and plants as well as a preparation method and application of the fusion vesicle, and relates to the technical field of biomedicine. The fusion vesicle comprises a mixed membrane structure formed by fusing a bacterial outer membrane vesicle and a plant thylakoid membrane, wherein the bacteria are gram negative bacteria, and the plant thylakoid is a spinach thylakoid. The fusion vesicle of the present invention combines the characteristics of the bacterial outer membrane vesicle and the plant capsular membrane, the structure of the vesicle is uniform, the vesicle can efficiently and rapidly reach the tumor, the tumor targeting property is high, and the accumulation time is long; and the obvious effect is realized in the aspect of tumor treatment.

The invention discloses a homologous targeting tannic acid copper albumin composite nanoparticle and preparation method and anti-tumor application thereof. The targeted tannic acid copper albumin composite nanoparticle comprises a nano-particle inner core, a tannic acid and copper complex wrapped outside the nano-particle inner core and a cancer cell membrane with targeting ability, and the nanoparticle inner core is composed of albumin and glucose oxidase adsorbed on the albumin. The preparation method mainly adopts an ultrasonic mode, and is simple to operate, good in repeatability and controllable in size. The nanoparticle has homologous targeting property, the tannic acid copper complex and hydrogen peroxide can be subjected to Fenton-like reaction, and generated hydroxyl free radicals can effectively kill cancer cells. In addition, under the combined action of glucose oxidase, the content of hydrogen peroxide in a cancer cell microenvironment is increased, and the effect of the Fenton-like reaction is further improved; and the tannic acid copper complex can generate ROS under the excitation of ultrasonic waves, and has the effect of cooperatively killing tumor cells.